Literature DB >> 11841410

High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma.

Ken Kuramoto1, Akira Sakai, Kazushi Shigemasa, Yasuo Takimoto, Hideki Asaoku, Takako Tsujimoto, Kenji Oda, Akiro Kimura, Toshihiro Uesaka, Hiromitsu Watanabe, Osamu Katoh.   

Abstract

We evaluated the level of MCL1 gene expression using quantitative reverse transcription polymerase chain reaction in lymph nodes of patients with non-Hodgkin lymphoma (NHL). MCL1 expression in patients in complete remission (CR) was significantly lower than in patients with progressive disease (PD, P = 0.0043). The disease-free survival rate was significantly higher in patients with MCL1 levels below the median level (P = 0.007). We also found that the level of expression of MCL1 mRNA was related to that of vascular endothelial growth factor mRNA in NHL lymph nodes. Our data suggest that the MCL1 expression level could be considered a prognostic factor in NHL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841410     DOI: 10.1046/j.1365-2141.2002.03253.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice.

Authors:  Kerstin Brinkmann; Stephanie Grabow; Craig D Hyland; Charis E Teh; Warren S Alexander; Marco J Herold; Andreas Strasser
Journal:  Cell Death Differ       Date:  2017-08-11       Impact factor: 15.828

2.  A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

Authors:  Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; Michael LeBlanc; Brent Farnsworth; Maria Iannone; Martha J Glenn; Richard I Fisher; Thomas P Miller
Journal:  Blood       Date:  2012-06-25       Impact factor: 22.113

Review 3.  Survival control of malignant lymphocytes by anti-apoptotic MCL-1.

Authors:  Y Fernández-Marrero; S Spinner; T Kaufmann; P J Jost
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

Review 4.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

Review 5.  The role of angiogenesis in human non-Hodgkin lymphomas.

Authors:  Domenico Ribatti; Beatrice Nico; Girolamo Ranieri; Giorgina Specchia; Angelo Vacca
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

Review 6.  Targeting MCL-1 in hematologic malignancies: Rationale and progress.

Authors:  Andrew H Wei; Andrew W Roberts; Andrew Spencer; Aaron Seth Rosenberg; David Siegel; Roland B Walter; Sean Caenepeel; Paul Hughes; Zach McIver; Khalid Mezzi; Phuong Khanh Morrow; Anthony Stein
Journal:  Blood Rev       Date:  2020-02-21       Impact factor: 8.250

7.  Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).

Authors:  Kristen Ganjoo; Fangxin Hong; Sandra J Horning; Randy D Gascoyne; Yasodha Natkunam; Lode J Swinnen; Thomas M Habermann; Brad S Kahl; Ranjana H Advani
Journal:  Leuk Lymphoma       Date:  2013-07-29

8.  Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.

Authors:  S Galimberti; M Petrini
Journal:  Cancer Manag Res       Date:  2010-06-28       Impact factor: 3.989

Review 9.  Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?

Authors:  K Brinkmann; H Kashkar
Journal:  Cell Death Dis       Date:  2014-03-06       Impact factor: 8.469

10.  Gene expression-based risk score in diffuse large B-cell lymphoma.

Authors:  Caroline Bret; Bernard Klein; Jérôme Moreaux
Journal:  Oncotarget       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.